Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549595 · ClinicalTrials.gov registry record · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
A Phase 3 study of Untreated Follicular Lymphoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,018
- Enrollment target
- 20
- Study locations
NCT06549595: Recruiting Phase 3 study of Untreated Follicular Lymphoma, sponsored by AstraZeneca.
NCT06549595 is a Phase 3 study of Untreated Follicular Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,018 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06549595, a Phase 3 study of Untreated Follicular Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,018 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Primary Outcome
Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in physical examination and safety procedures.
Conditions Studied
Interventions
- DRUG Surovatamig
- DRUG R-CHOP
- DRUG R-CVP
- DRUG BR
Study Locations (20)
Other
- Research Site - Garran
- Research Site - Heidelberg
- Research Site - Macquarie University
- Research Site - Nedlands
- Research Site - Brussels
- Research Site - Brussels
- Research Site - Ghent
- Research Site - Mechelen
- Research Site - Porto Alegre
- Research Site - São Paulo
- Research Site - São Paulo
New York
- Research Site - New York
- Research Site - New York
Alaska
- Research Site - Anchorage
Colorado
- Research Site - Aurora
Connecticut
- Research Site - New Haven
Michigan
- Research Site - Ann Arbor
Tennessee
- Research Site - Nashville
Manitoba
- Research Site - Winnipeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,018 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2031-11-26 |
| Phase | Phase 3 |
What NCT06549595 shows while recruiting
NCT06549595 is an interventional study that assigns participants to a tested intervention. Its 1,018 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher).
The record links to 1 condition, with Untreated Follicular Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Surovatamig is the first listed.
NCT06549595 names 20 study sites across 9 states, led by Other, New York, Alaska.
Frequently Asked Questions
What is clinical trial NCT06549595 about?
NCT06549595 is a clinical study titled "A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients". This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with un...
What is the current status of trial NCT06549595?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,018 participants. The study started on 2024-08-07. Estimated completion is 2031-11-26.
What conditions does trial NCT06549595 study?
This clinical trial studies the following conditions: Untreated Follicular Lymphoma.
What interventions are being tested in trial NCT06549595?
The interventions under investigation include: Surovatamig (DRUG), R-CHOP (DRUG), R-CVP (DRUG), BR (DRUG).
Who is sponsoring clinical trial NCT06549595?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06549595 being conducted?
This trial has 20 study locations across Alaska, Colorado, Connecticut, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06549595's enrollment target sits among peer trials
1,018 293rd of 2000 higher than 1,708 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI